Cardiol Therapeutics, Inc. (CRDL)
1.12
-0.03
(-2.61%)
USD |
NASDAQ |
Oct 23, 16:00
1.12
0.00 (0.00%)
After-Hours: 20:00
Cardiol Therapeutics Enterprise Value : 111.48M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 111.48M |
| October 22, 2026 | 114.96M |
| October 21, 2026 | 117.28M |
| October 20, 2026 | 114.96M |
| October 19, 2026 | 109.17M |
| October 16, 2026 | 109.17M |
| October 15, 2026 | 114.96M |
| October 14, 2026 | 113.80M |
| October 13, 2026 | 120.75M |
| October 12, 2026 | 118.44M |
| October 09, 2026 | 124.23M |
| October 08, 2026 | 132.34M |
| October 07, 2026 | 134.66M |
| October 06, 2026 | 133.50M |
| October 05, 2026 | 134.66M |
| October 02, 2026 | 145.09M |
| October 01, 2026 | 162.47M |
| September 30, 2026 | 174.06M |
| September 29, 2026 | 177.54M |
| September 28, 2026 | 177.54M |
| September 25, 2026 | 179.86M |
| September 24, 2026 | 182.17M |
| September 23, 2026 | 186.81M |
| September 22, 2026 | 200.71M |
| September 21, 2026 | 197.24M |
| Date | Value |
|---|---|
| September 18, 2026 | 198.98M |
| September 17, 2026 | 197.24M |
| September 16, 2026 | 201.87M |
| September 15, 2026 | 196.08M |
| September 14, 2026 | 212.30M |
| September 11, 2026 | 212.88M |
| September 10, 2026 | 211.14M |
| September 09, 2026 | 246.49M |
| September 08, 2026 | 238.96M |
| September 04, 2026 | 236.64M |
| September 03, 2026 | 232.00M |
| September 02, 2026 | 233.16M |
| September 01, 2026 | 230.84M |
| August 31, 2026 | 210.56M |
| August 28, 2026 | 206.51M |
| August 27, 2026 | 220.41M |
| August 26, 2026 | 229.69M |
| August 25, 2026 | 213.46M |
| August 24, 2026 | 197.24M |
| August 21, 2026 | 197.24M |
| August 20, 2026 | 200.14M |
| August 19, 2026 | 208.83M |
| August 18, 2026 | 201.29M |
| August 17, 2026 | 190.28M |
| August 14, 2026 | 190.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 5.455M |
| NervGen Pharma Corp. | 91.00M |
| Milestone Pharmaceuticals, Inc. | 51.92M |
| Appili Therapeutics, Inc. | 10.20M |
| Clearmind Medicine, Inc. | -12.56M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.393M |
| Total Expenses (Quarterly) | 4.393M |
| EPS Diluted (Quarterly) | -0.0382 |
| Earnings Yield | -22.11% |
| Normalized Earnings Yield | -22.35 |